Nevirapine Retard Sandoz (Nevirapine)

Nevirapine binds to a specific non‑nucleoside site on the HIV‑1 reverse transcriptase enzyme, causing a structural change that blocks the enzyme’s ability to convert viral RNA into DNA. This interruption stops the virus from replicating inside host cells, helping to lower viral load.

The prescribed dose of Nevirapine Retard Sandoz is determined by the treating physician based on the patient’s clinical status, prior therapy, and laboratory results. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Nevirapine may be used in pregnancy only when the benefits outweigh potential risks, and it is sometimes included in regimens to prevent mother‑to‑child transmission of HIV. Breastfeeding while on nevirapine is generally not recommended unless the infant is also receiving appropriate antiretroviral prophylaxis. Clinical judgment is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nevirapine shares the NNRTI class with drugs such as efavirenz and rilpivirine. Compared with efavirenz, nevirapine has a lower incidence of central nervous system side effects but a higher risk of skin and hepatic reactions. Choice of agent depends on patient tolerance, resistance profile, and co‑medications.

Nevirapine Retard Sandoz tablets should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and discard any tablets that appear discoloured or damaged.

The tablet is taken orally, usually with food to improve tolerability. Patients should swallow the tablet whole and follow the dosing schedule prescribed by their healthcare provider, ensuring consistent timing each day to maintain steady drug levels.

The most serious adverse events include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, and potentially fatal hepatotoxicity. Early signs of rash or liver dysfunction require immediate medical evaluation and possible discontinuation of therapy.

Nevirapine is contraindicated in patients with a known hypersensitivity to nevirapine or any of its components, and in individuals with a history of severe liver disease or prior severe cutaneous adverse reactions to NNRTIs. Caution is also advised for patients with pre‑existing hepatic impairment.